Novel oral anticoagulants for venous thromboembolism prophylaxis after total hip or knee replacement: an update on rivaroxaban (xarelto).
作者信息
Stacy Zachary
出版信息
P T. 2013 Jan;38(1):45-50.
Abstract
摘要
相似文献
1
2
Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.利伐沙班预防静脉血栓栓塞症：一项单一技术评估。
Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07.
3
Comparative safety and efficacy of antithrombotics in the management of venous thromboembolism after knee or hip replacement surgery: focus on rivaroxaban.抗血栓药物在膝关节或髋关节置换术后静脉血栓栓塞管理中的比较安全性和有效性：聚焦于利伐沙班
Clin Pharmacol. 2013 Aug 2;5:143-8. doi: 10.2147/CPAA.S26647. eCollection 2013.
4
A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.比较利伐沙班和达比加群酯与依诺肝素钠作为爱尔兰医疗保健环境下全髋关节和全膝关节置换术后血栓预防的成本效益模型。
Pharmacoeconomics. 2009;27(10):829-46. doi: 10.2165/11313800-000000000-00000.
5
6
Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes.全髋关节或膝关节置换术后短期预防静脉血栓栓塞：一项调查症状性结局的前瞻性研究的荟萃分析
Arch Intern Med. 2002 Jul 8;162(13):1465-71. doi: 10.1001/archinte.162.13.1465.
7
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].[阿哌沙班预防全膝关节或全髋关节置换术患者静脉血栓栓塞对国家卫生系统的预算影响]
Rev Esp Salud Publica. 2012 Dec;86(6):601-12. doi: 10.4321/S1135-57272012000600006.
8
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.新型口服抗凝药物：临床药理学、适应证及实际考虑。
Eur J Clin Pharmacol. 2013 Sep;69(9):1617-33. doi: 10.1007/s00228-013-1510-z. Epub 2013 Apr 26.
9
Implications of new anticoagulants in primary practice.新型抗凝药物在初级实践中的应用。
Int J Clin Pract. 2013 Feb;67(2):139-56. doi: 10.1111/ijcp.12023.
10
Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.利伐沙班：用于全髋关节或全膝关节置换术后预防静脉血栓栓塞症的研究进展。
Am J Cardiovasc Drugs. 2012 Feb 1;12(1):57-72. doi: 10.2165/11208470-000000000-00000.
引用本文的文献
1
Direct Oral Anticoagulants in the Prevention of Venous Thromboembolism Following Surgery for Hip Fracture in Older Adults: A Population-Based Cohort Study.直接口服抗凝剂预防老年髋部骨折手术后静脉血栓栓塞：一项基于人群的队列研究。
Geriatr Orthop Surg Rehabil. 2020 Jan 13;11:2151459319897520. doi: 10.1177/2151459319897520. eCollection 2020.
本文引用的文献
1
Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.骨科手术患者静脉血栓栓塞症的预防：抗血栓治疗和血栓预防，第 9 版：美国胸科医师学会基于证据的临床实践指南。
Chest. 2012 Feb;141(2 Suppl):e278S-e325S. doi: 10.1378/chest.11-2404.
2
Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty.择期髋关节和膝关节置换术患者的静脉血栓栓塞症预防。
J Am Acad Orthop Surg. 2011 Dec;19(12):768-76. doi: 10.5435/00124635-201112000-00007.
3
Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.从美国支付者角度看利伐沙班与依诺肝素预防术后静脉血栓栓塞的成本和结局。
J Med Econ. 2011;14(6):824-34. doi: 10.3111/13696998.2011.623203. Epub 2011 Oct 24.
4
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.在健康受试者中，用凝血酶原复合物浓缩物逆转利伐沙班和达比加群：一项随机、安慰剂对照、交叉研究。
Circulation. 2011 Oct 4;124(14):1573-9. doi: 10.1161/CIRCULATIONAHA.111.029017. Epub 2011 Sep 6.
5
Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.全髋关节或全膝关节置换术后利伐沙班的成本效益。
Am J Manag Care. 2011 Feb;17(1 Suppl):S22-6.
6
SCIP core measures: Deep impact.
Nurs Manage. 2011 May;42(5):24-30; quiz 30-1. doi: 10.1097/01.NUMA.0000396344.54830.0d.
7
Preventing postsurgical venous thromboembolism: pharmacological approaches.预防术后静脉血栓栓塞症：药物治疗方法。
Semin Thromb Hemost. 2011 Apr;37(3):252-66. doi: 10.1055/s-0031-1273089. Epub 2011 Mar 31.
8
Practice patterns in the use of venous thromboembolism prophylaxis after total joint arthroplasty--insights from the Multinational Global Orthopaedic Registry (GLORY).全关节置换术后静脉血栓栓塞预防的应用模式——来自多国全球骨科注册中心（GLORY）的见解
Am J Orthop (Belle Mead NJ). 2010 Sep;39(9 Suppl):14-21.
9
Laboratory assessment of new anticoagulants.新型抗凝剂的实验室评估。
Clin Chem Lab Med. 2011 May;49(5):761-72. doi: 10.1515/CCLM.2011.134. Epub 2011 Feb 3.
10
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.口服达比加群酯与依诺肝素预防初次全髋关节置换术后血栓形成（RE-NOVATE II*）。一项随机、双盲、非劣效性试验。
Thromb Haemost. 2011 Apr;105(4):721-9. doi: 10.1160/TH10-10-0679. Epub 2011 Jan 12.
Zotero 插件